Liquid purification or separation – Processes – Liquid/liquid solvent or colloidal extraction or diffusing...
Reexamination Certificate
2011-01-25
2011-01-25
Menon, Krishnan S (Department: 1736)
Liquid purification or separation
Processes
Liquid/liquid solvent or colloidal extraction or diffusing...
C210S500270, C210S500360, C210S651000
Reexamination Certificate
active
07875183
ABSTRACT:
There is provided a method of reducing blood free light chain concentration in a subject, the method comprising the step of subjecting the subject's blood to haemodialysis, haemodiafiltration or haemofiltration. There is also provided the use of a dialysis membrane which is a membrane that allows passage of molecules having a molecular weight of up to 45 kDa in presence of whole blood, and has a molecular weight exclusion limit in water of about 200 kDa in the preparation of a haemodialysis unit for conducting haemodialysis, haemodiafiltration or haemofiltration on a subject to reduce blood free light chain concentration in the patient.
REFERENCES:
patent: 2004/0214761 (2004-10-01), Raison et al.
patent: 2006/0144782 (2006-07-01), Buck
patent: WO02/49745 (2002-06-01), None
patent: 2004/056460 (2004-07-01), None
patent: 2006/079816 (2006-08-01), None
High-Cut Off Protein Permeable Membrane, GAMBRO, retrieved from http://www.gambro.at/—rtf-gambro/CMS—fg475d6180139d7—orig—1512.pdf on Apr. 14, 2009.
Conventional Chemotherapy Treatment for Mulitple Myeloma, Multiple Myeloma Research Foundation (MMRF) [retrieved from http://www.multiplemyeloma.org/treatments/3.02.php on Apr. 14, 2009].
Blade, J., “Management of renal, hematologic, and infectious complications”, Myeloma: Biology and Management, 3rd edition, pp. 251-267.
Bradwell, A.R., “Diseases with increased polyclonal free light chains”, Serum Free Light Chain Analysis, 2nd edition, Birmingham, UK, The Binding Site Ltd., pp. 145-151.
Bradwell et al., “Rapid removal of free light chains from Serum by hemodialysis for patients with myeloma kidney”, Blood, the Journal of the American Society of Hematology, vol. 106, No. 11, Nov. 16, 2005, 1 page.
Bradwell et al., “Serum free light chain immunoassays and their clinical application”, Clinical and Applied Immunology Reviews, vol. 3, No. 1-2, Nov. 2002, pp. 17-33.
Bradwell et al., “Diseases with increased polyclonal free light chains,” Serum Free Light Chain Analysis, 3rd Edition, Birmingham, UK, The Binding Site Ltd., pp. 175-185.
Clark et al., “Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial”, Ann Intern Med., vol. 143, No. 11, 2005, pp. 777-784.
Clark et al., Haematologica/ the hematology journal, vol. 90, supplement No. 1, Apr. 2005, p. 117.
Cohen et al., “Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients”, Nephrology Dialysis Transplantation, vol. 17, 2002, pp. 879-883.
Johnson et al., “Treatment of renal failure associated with multiple myeloma—plasmapheresis, hemodialysis, and chemotherapy”, Arch. Intern. Med., vol. 150, Apr. 1990, pp. 863-869.
Mead et al., “Serum free light chains for monitoring multiple myeloma”, British Journal of Haematology, vol. 126, pp. 348-354.
Morgera et al., “High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure”, Nephrol. Dial. Transplant vol. 18, 2003, pp. 2570-2576.
Morgera et al., “Intermittent high permeability hemofiltration in septic patients with acute renal failure”, Intensive Care Med. vol. 29, 2003, 1989-1995.
Morgera et al., “Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status”, American Journal of Kidney Diseases, vol. 43, No. 3, Mar. 2004, pp. 444-453.
Naka et al., “Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report”, Critical Care, vol. 9 No. 2, Apr. 2005, pp. 90-95.
Nowrousian et al., “Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma”, Clinical Cancer Res., vol. 11(24), Dec. 15, 2005, pp. 8706-8714.
Pratt et al., “The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains,” Leukemia and Lymphoma, vol. 47(1), Jan. 2006, pp. 21-28.
Ritz, E., “Cast nephropathy in myeloma—does PACAP38, a new member of the vasoactive intestinal peptide family, open a therapeutic window?”, Journal of the American Society of Nephrology, 2006, pp. 911-913.
Russo et al., “Renal handling of albumin: a critical review of basic concepts and perspective”, American Journal of Kidney Diseases, vol. 39, No. 5, May 2002, pp. 899-919.
Sanders et al., “Pathobiology of cast nephropathy from human Bence Jones proteins”, J. Clin. Invest, vol. 89, Feb. 1992, pp. 630-639.
Solomon A., “Light chains of human immunoglobulins” Methods in Enzymology, vol. 116, 1985, pp. 101-121.
Tauro et al., “Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure”, Bone Marrow Transplantation, vol. 30, 2002, pp. 471-473.
Ward R.A., “Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application?” Journal of the American Society of Nephrology, vol. 16, 2005, pp. 2421-2430.
Winearls C.G., “Acute myeloma kidney”, Kidney International, vol. 48, 1995, pp. 1347-1361.
Winearls C.G., “Myeloma kidney”, Comprehensive Clinical Nephrology, 2nd edition, Johnson & Feehally, Harcourt Publishers, chapter 17, pp. 235-241.
Ying et al., “Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein”, American Journal of Pathology, vol. 158, No. 5, May 2001, pp. 1859-1866.
Zuccelli et al., “Controlled plasma exchange trial in acute renal failure due to multiple myeloma”, Kidney International, vol. 33, 1988, pp. 1175-1180.
Hutchison et al., “Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies,” Journal of the American Society of Nephrology, vol. 18, 2007, pp. 886-895.
Drueke, T.B., “Beta2-microglobulin and amyloidosis,” Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and transplant Association -European Renal Association, vol. 15, Suppl. 1, (2000), pp. 17-24.
Machiguchi et al, “Efficacy of haemodiafiltration treatment with PEPA dialysis membranes in plasma free light chain removal in a patient with primary amyloidosis,” Nephrology Dialysis Transplantation, vol. 17, Sep. 2002, pp. 1689-1691.
Bradwell Arthur Randell
Goehl Hermann
Storr Markus
Barnes & Thornburg LLP
Bass Dirk
Gambro Lundia AB
Menon Krishnan S
The Binding Site Group Limited
LandOfFree
Method of removing antibody free light chains from blood does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of removing antibody free light chains from blood, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of removing antibody free light chains from blood will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659998